Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 15;86(11):1014-21.
doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.

Multiple sclerosis prevalence in the United States commercially insured population

Piyameth Dilokthornsakul  1 , Robert J Valuck  1 , Kavita V Nair  1 , John R Corboy  1 , Richard R Allen  1 , Jonathan D Campbell  2
Affiliations

Multiple sclerosis prevalence in the United States commercially insured population

Piyameth Dilokthornsakul et al. Neurology. .

Abstract

Objective: To estimate the US commercially insured multiple sclerosis (MS) annual prevalence from 2008 to 2012.

Methods: The study was a retrospective analysis using PharMetrics Plus, a nationwide claims database for over 42 million covered US representative lives. Annual point prevalence required insurance eligibility during an entire year. Our primary annual MS identification algorithm required 2 inpatient claims coded ICD-9 340 or 3 outpatient claims coded ICD-9 340 or 1 MS-indicated disease-modifying therapy claim. Age-adjusted annual prevalence estimates were extrapolated to the US population using US Census data.

Results: The 2012 MS prevalence was 149.2 per 100,000 individuals (95% confidence interval 147.6-150.9). Prevalence was consistent over 2008-2012. Female participants were 3.13 times more likely to have MS. The highest prevalence was in participants aged 45-49 years (303.5 per 100,000 individuals [295.6-311.5]). The East Census region recorded the highest prevalence (192.1 [188.2-196.0]); the West Census region recorded the lowest prevalence (110.7 [105.5-116.0]). The US annual 2012 MS extrapolated population was 403,630 (387,445-419,833).

Conclusions: MS prevalence rates from a representative commercially insured database were higher than or consistent with prior US estimates. For further accuracy improvement of US prevalence estimates, results should be confirmed after validation of MS identification algorithms, and should be expanded to other US populations, including the government-insured and the uninsured.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Multiple sclerosis prevalence in the US insured population by sex (all algorithms)
Figure 2
Figure 2. Multiple sclerosis prevalence in the US insured population by age (all years, primary algorithm)
Figure 3
Figure 3. 2012 Multiple sclerosis prevalence in the US insured population by region
Figure 4
Figure 4. Multiple sclerosis prevalence in the US insured population by region (all years, primary algorithm)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care 2011;17(suppl 5):S139–S145. - PubMed
    1. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs 2004;18:561–574. - PubMed
    1. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999;53:1098–1103. - PubMed
    1. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: II: impact on employment and social functioning. Neurology 1991;41:692–696. - PubMed
    1. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ 2013;16:639–647. - PubMed

Publication types